IPA logo

ImmunoPrecise Antibodies (IPA) Net Income

Annual Net Income

-$20.12 M
-$151.60 K-0.76%

April 30, 2024


Summary


Performance

IPA Net Income Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherIPAprofitabilitymetrics:

Quarterly Net Income

-$1.87 M
+$1.05 M+35.95%

October 31, 2024


Summary


Performance

IPA Quarterly Net Income Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherIPAprofitabilitymetrics:

TTM Net Income

-$20.26 M
-$96.40 K-0.48%

October 31, 2024


Summary


Performance

IPA TTM Net Income Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherIPAprofitabilitymetrics:

Net Income Formula

Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses

IPA Net Income Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-0.8%+36.0%-0.5%
3 y3 years-258.8%+36.0%-0.5%
5 y5 years-248.1%+36.0%-0.5%

IPA Net Income Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-258.8%at low-5.4%+85.9%-96.9%at low
5 y5-year-443.1%at low-432.9%+85.9%-957.6%at low
alltimeall time<-9999.0%at low-500.8%+85.9%-5781.5%at low

ImmunoPrecise Antibodies Net Income History

DateAnnualQuarterlyTTM
Oct 2024
-
-$1.87 M(-36.0%)
-$20.26 M(+0.5%)
Jul 2024
-
-$2.92 M(-78.0%)
-$20.16 M(+1.8%)
Apr 2024
-$20.12 M(+0.8%)
-$13.29 M(+510.8%)
-$19.80 M(+92.4%)
Jan 2024
-
-$2.18 M(+22.7%)
-$10.29 M(-11.3%)
Oct 2023
-
-$1.77 M(-30.7%)
-$11.60 M(-24.4%)
Jul 2023
-
-$2.56 M(-32.4%)
-$15.35 M(-23.5%)
Apr 2023
-$19.97 M(+50.0%)
-$3.78 M(+8.5%)
-$20.07 M(+0.6%)
Jan 2023
-
-$3.48 M(-36.9%)
-$19.95 M(+2.4%)
Oct 2022
-
-$5.52 M(-24.2%)
-$19.49 M(+8.6%)
Jul 2022
-
-$7.28 M(+98.8%)
-$17.95 M(+35.0%)
Apr 2022
-$13.32 M(+137.4%)
-$3.66 M(+21.3%)
-$13.29 M(-2.4%)
Jan 2022
-
-$3.02 M(-24.2%)
-$13.63 M(+17.3%)
Oct 2021
-
-$3.98 M(+51.5%)
-$11.61 M(+45.5%)
Jul 2021
-
-$2.63 M(-34.2%)
-$7.98 M(+38.7%)
Apr 2021
-$5.61 M(+51.4%)
-$4.00 M(+297.4%)
-$5.75 M(+135.2%)
Jan 2021
-
-$1.01 M(+186.5%)
-$2.45 M(+27.7%)
Oct 2020
-
-$350.90 K(-12.6%)
-$1.92 M(-26.2%)
Jul 2020
-
-$401.30 K(-41.7%)
-$2.59 M(-30.0%)
Apr 2020
-$3.71 M(-35.9%)
-$688.00 K(+44.7%)
-$3.71 M(-37.2%)
Jan 2020
-
-$475.50 K(-53.8%)
-$5.91 M(-6.6%)
Oct 2019
-
-$1.03 M(-32.0%)
-$6.32 M(-1.7%)
Jul 2019
-
-$1.51 M(-47.5%)
-$6.43 M(+11.6%)
Apr 2019
-$5.78 M(+42.6%)
-$2.88 M(+223.8%)
-$5.76 M(+25.2%)
Jan 2019
-
-$891.00 K(-21.8%)
-$4.60 M(-1.4%)
Oct 2018
-
-$1.14 M(+34.9%)
-$4.67 M(+9.8%)
Jul 2018
-
-$845.00 K(-51.1%)
-$4.25 M(+4.8%)
Apr 2018
-$4.05 M(-0.8%)
-$1.73 M(+80.3%)
-$4.06 M(+25.6%)
Jan 2018
-
-$957.70 K(+32.6%)
-$3.23 M(-42.3%)
Oct 2017
-
-$722.10 K(+11.3%)
-$5.60 M(+14.7%)
Jul 2017
-
-$649.00 K(-27.9%)
-$4.88 M(+15.1%)
Apr 2017
-$4.09 M(>+9900.0%)
-$899.60 K(-73.0%)
-$4.24 M(+27.0%)
Jan 2017
-
-$3.33 M(>+9900.0%)
-$3.34 M(+7520.1%)
Sep 2016
-
-$3600.00(-50.0%)
-$43.80 K(+3.3%)
Jun 2016
-
-$7200.00(+132.3%)
-$42.40 K(+48.8%)
Mar 2016
-
-$3100.00(-89.6%)
-$28.50 K(+22.8%)
Dec 2015
-$25.00 K(-55.7%)
-
-
Dec 2015
-
-$29.90 K(+1259.1%)
-$23.20 K(+231.4%)
Sep 2015
-
-$2200.00(-132.8%)
-$7000.00(-77.9%)
Jun 2015
-
$6700.00(+204.5%)
-$31.70 K(-14.6%)
Mar 2015
-
$2200.00(-116.1%)
-$37.10 K(-34.2%)
Dec 2014
-$56.40 K(-183.7%)
-
-
Dec 2014
-
-$13.70 K(-49.1%)
-$56.40 K(-34.7%)
Sep 2014
-
-$26.90 K(-2169.2%)
-$86.40 K(-207.3%)
Jun 2014
-
$1300.00(-107.6%)
$80.50 K(+20.1%)
Mar 2014
-
-$17.10 K(-60.9%)
$67.00 K(+0.8%)
Dec 2013
$67.40 K(-170.4%)
-
-
Dec 2013
-
-$43.70 K(-131.2%)
$66.50 K(+42.4%)
Sep 2013
-
$140.00 K(-1247.5%)
$46.70 K(-142.1%)
Jun 2013
-
-$12.20 K(-30.7%)
-$110.80 K(+10.7%)
Mar 2013
-
-$17.60 K(-72.3%)
-$100.10 K(+3.8%)
Dec 2012
-$95.80 K(-65.6%)
-
-
Dec 2012
-
-$63.50 K(+262.9%)
-$96.40 K(-34.8%)
Sep 2012
-
-$17.50 K(+1066.7%)
-$147.90 K(-24.2%)
Jun 2012
-
-$1500.00(-89.2%)
-$195.00 K(-23.9%)
Mar 2012
-
-$13.90 K(-87.9%)
-$256.40 K(-8.2%)
Dec 2011
-$278.80 K(-94.6%)
-
-
Dec 2011
-
-$115.00 K(+78.0%)
-$279.40 K(-94.6%)
Sep 2011
-
-$64.60 K(+2.7%)
-$5.21 M(+0.3%)
Jun 2011
-
-$62.90 K(+70.5%)
-$5.20 M(+0.3%)
Mar 2011
-
-$36.90 K(-99.3%)
-$5.18 M(-0.4%)
Dec 2010
-$5.13 M(+488.1%)
-
-
Dec 2010
-
-$5.05 M(>+9900.0%)
-$5.21 M(+434.0%)
Sep 2010
-
-$48.70 K(-0.2%)
-$975.40 K(+0.8%)
Jun 2010
-
-$48.80 K(-18.8%)
-$967.60 K(+1.5%)
Mar 2010
-
-$60.10 K
-$953.00 K
DateAnnualQuarterlyTTM
Dec 2009
-$872.80 K(+95.9%)
-
-
Dec 2009
-
-$817.80 K(+1899.5%)
-$927.20 K(+175.0%)
Sep 2009
-
-$40.90 K(+19.6%)
-$337.20 K(+7.9%)
Jun 2009
-
-$34.20 K(-0.3%)
-$312.40 K(-0.2%)
Mar 2009
-
-$34.30 K(-84.9%)
-$312.90 K(-25.9%)
Dec 2008
-$445.50 K(-37.1%)
-
-
Dec 2008
-
-$227.80 K(+1314.9%)
-$422.50 K(+12.7%)
Sep 2008
-
-$16.10 K(-53.6%)
-$375.00 K(-1.5%)
Jun 2008
-
-$34.70 K(-75.9%)
-$380.80 K(-54.1%)
Mar 2008
-
-$143.90 K(-20.2%)
-$830.20 K(+17.2%)
Dec 2007
-$707.80 K(+98.2%)
-
-
Dec 2007
-
-$180.30 K(+723.3%)
-$708.40 K(+21.1%)
Sep 2007
-
-$21.90 K(-95.5%)
-$585.00 K(-2.2%)
Jun 2007
-
-$484.10 K(+2090.5%)
-$598.00 K(+83.5%)
Mar 2007
-
-$22.10 K(-61.2%)
-$325.80 K(-8.0%)
Dec 2006
-$357.10 K(-359.7%)
-
-
Dec 2006
-
-$56.90 K(+63.0%)
-$354.20 K(-309.3%)
Sep 2006
-
-$34.90 K(-83.5%)
$169.20 K(-3945.5%)
Jun 2006
-
-$211.90 K(+319.6%)
-$4400.00(-102.6%)
Mar 2006
-
-$50.50 K(-110.8%)
$170.30 K(-52.2%)
Dec 2005
$137.50 K(-195.4%)
-
-
Dec 2005
-
$466.50 K(-323.7%)
$356.60 K(-311.1%)
Sep 2005
-
-$208.50 K(+460.5%)
-$168.90 K(-783.8%)
Jun 2005
-
-$37.20 K(-127.4%)
$24.70 K(-24.2%)
Mar 2005
-
$135.80 K(-330.2%)
$32.60 K(-122.4%)
Dec 2004
-$144.10 K(-64.4%)
-
-
Dec 2004
-
-$59.00 K(+296.0%)
-$145.40 K(-65.9%)
Sep 2004
-
-$14.90 K(-49.1%)
-$426.80 K(-1.4%)
Jun 2004
-
-$29.30 K(-30.6%)
-$432.80 K(-1.2%)
Mar 2004
-
-$42.20 K(-87.6%)
-$438.00 K(+3.7%)
Dec 2003
-$404.40 K(+123.4%)
-
-
Dec 2003
-
-$340.40 K(+1528.7%)
-$422.50 K(+130.1%)
Sep 2003
-
-$20.90 K(-39.4%)
-$183.60 K(+0.2%)
Jun 2003
-
-$34.50 K(+29.2%)
-$183.30 K(+0.2%)
Mar 2003
-
-$26.70 K(-73.7%)
-$182.90 K(+1.0%)
Dec 2002
-$181.00 K(+19.0%)
-
-
Dec 2002
-
-$101.50 K(+392.7%)
-$181.00 K(+70.8%)
Sep 2002
-
-$20.60 K(-39.6%)
-$106.00 K(-24.0%)
Jun 2002
-
-$34.10 K(+37.5%)
-$139.50 K(-21.1%)
Mar 2002
-
-$24.80 K(-6.4%)
-$176.70 K(-0.6%)
Dec 2001
-$152.10 K(+68.3%)
-
-
Dec 2001
-
-$26.50 K(-51.0%)
-$177.70 K(+0.7%)
Sep 2001
-
-$54.10 K(-24.1%)
-$176.40 K(+28.3%)
Jun 2001
-
-$71.30 K(+176.4%)
-$137.50 K(+49.5%)
Mar 2001
-
-$25.80 K(+2.4%)
-$92.00 K(+1.8%)
Dec 2000
-$90.40 K(-89.2%)
-
-
Dec 2000
-
-$25.20 K(+65.8%)
-$90.40 K(-89.9%)
Sep 2000
-
-$15.20 K(-41.1%)
-$895.20 K(+6.1%)
Jun 2000
-
-$25.80 K(+6.6%)
-$843.40 K(+1.5%)
Mar 2000
-
-$24.20 K(-97.1%)
-$831.10 K(-1.7%)
Dec 1999
-$838.10 K(-0.7%)
-
-
Dec 1999
-
-$830.00 K(-2367.8%)
-$845.10 K(+12.6%)
Sep 1999
-
$36.60 K(-371.1%)
-$750.30 K(-5.2%)
Jun 1999
-
-$13.50 K(-64.7%)
-$791.80 K(-2.7%)
Mar 1999
-
-$38.20 K(-94.8%)
-$813.60 K(-0.3%)
Dec 1998
-$844.30 K(+53.0%)
-
-
Dec 1998
-
-$735.20 K(>+9900.0%)
-$816.30 K(+48.3%)
Sep 1998
-
-$4900.00(-86.1%)
-$550.60 K(-3.6%)
Jun 1998
-
-$35.30 K(-13.7%)
-$571.10 K(-4.0%)
Mar 1998
-
-$40.90 K(-91.3%)
-$594.80 K(+9.5%)
Dec 1997
-$552.00 K(+4.5%)
-
-
Dec 1997
-
-$469.50 K(+1748.4%)
-$543.40 K(+635.3%)
Sep 1997
-
-$25.40 K(-56.9%)
-$73.90 K(+52.4%)
Jun 1997
-
-$59.00 K(-661.9%)
-$48.50 K(-561.9%)
Mar 1997
-
$10.50 K
$10.50 K
Dec 1996
-$528.30 K
-
-

FAQ

  • What is ImmunoPrecise Antibodies annual net profit?
  • What is the all time high annual net income for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies annual net income year-on-year change?
  • What is ImmunoPrecise Antibodies quarterly net profit?
  • What is the all time high quarterly net income for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies quarterly net income year-on-year change?
  • What is ImmunoPrecise Antibodies TTM net profit?
  • What is the all time high TTM net income for ImmunoPrecise Antibodies?
  • What is ImmunoPrecise Antibodies TTM net income year-on-year change?

What is ImmunoPrecise Antibodies annual net profit?

The current annual net income of IPA is -$20.12 M

What is the all time high annual net income for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high annual net profit is $137.50 K

What is ImmunoPrecise Antibodies annual net income year-on-year change?

Over the past year, IPA annual net profit has changed by -$151.60 K (-0.76%)

What is ImmunoPrecise Antibodies quarterly net profit?

The current quarterly net income of IPA is -$1.87 M

What is the all time high quarterly net income for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high quarterly net profit is $466.50 K

What is ImmunoPrecise Antibodies quarterly net income year-on-year change?

Over the past year, IPA quarterly net profit has changed by +$1.05 M (+35.95%)

What is ImmunoPrecise Antibodies TTM net profit?

The current TTM net income of IPA is -$20.26 M

What is the all time high TTM net income for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies all-time high TTM net profit is $356.60 K

What is ImmunoPrecise Antibodies TTM net income year-on-year change?

Over the past year, IPA TTM net profit has changed by -$96.40 K (-0.48%)